![](/wp-content/uploads/2021/03/Viatris-announcement.png)
$599
Viatris Generic Rybelsus in the Pipeline; Viatris 2021 Investor Day
Viatris hosted its first Investor Day (view slides), and the company provided updates across its diabetes generics and biosimilars portfolio. Importantly, the company disclosed plans to develop a generic version of Novo Nordisk’s Rybelsus (oral semaglutide). Below, FENIX provides brief highlights from the Investor Day as well as insight into challenges and questions of generic Rybelsus development.